{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-027210","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2025-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.761360+00:00","generated_at":"2026-05-17T06:45:11.806291+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Vivos Therapeutics files prospectus supplement for up to $5.83M ATM offering","bullets":["Company may sell up to $5,830,572 of common stock through H.C. Wainwright as sales agent.","No shares had been sold under prior ATM agreement as of September 12, 2025.","Shelf registration statement S-3 (333-284834) declared effective by SEC on September 10, 2025.","Common stock par value $0.0001 per share; proceeds for general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-027210","json":"https://secwatch.observer/filing/0001641172-25-027210.json","markdown":"https://secwatch.observer/filing/0001641172-25-027210.md","text":"https://secwatch.observer/filing/0001641172-25-027210.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000164117225027210/0001641172-25-027210-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000164117225027210/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:45:11.806291+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}